Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2336805 + ritonavir
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GSK2336805 is an investigational small molecule inhibitor targeting the hepatitis C virus (HCV) non-structural protein 5A (NS5A), a key component in HCV replication. Ritonavir is a protease inhibitor primarily used as a pharmacokinetic enhancer due to its potent inhibition of cytochrome P450 3A4 (CYP3A4), thereby increasing plasma concentrations of co-administered drugs metabolized by this enzyme. In combination, GSK2336805 and ritonavir are studied for their potential in treating HCV infection, with ritonavir boosting the exposure of GSK2336805 by inhibiting its metabolism. This combination has been evaluated in Phase I clinical trials for safety and pharmacokinetics in healthy subjects[2][3]. Ritonavir is also approved as an antiretroviral agent for HIV-1 infection[1][4][7].
02
Targets
CYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on GSK2336805 + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2336805 + ritonavir.